MedTech Connect 2026 Investor of the Year: Y Combinator
MedTech Connect's best MedTech investor of 2025 wasn't a traditional venture capital firm. Most folks don't even think of them as MedTech investors; they're better known for consumer-facing software and SaaS. They've played a part in launching big general-market names, like Airbnb and Reddit. Also, because they're a seed-stage accelerator writing relatively small checks, their role is often overlooked.
Despite their under-the-radar status in MedTech, they play an important role in the ecosystem: they fund startups in the earliest stages, help them make progress, and introduce them to their next round of funding. Hundreds, if not thousands of investors attend their demo days, even though many of their startups already have term sheets. In a world where founders can spend the better part of a year fundraising, this can make a huge difference in the trajectory and ultimate success of a company.
Of course, founders want more than just investment. They want to get their products to market where they can make a difference in the lives of patients and clinicians. And founders want to achieve financial success for their employees, investors, and themselves.
And our MedTech Connect Investor of the Year did just that, adding a significant exit to their portfolio in November of 2025: BillionToOne.
And so, Y Combinator is MedTech Connect's inaugural Investor of the Year.
We recently published our 2026 MedTech VC Rankings, which ranked dozens of investors across capital deployed, exits, medtech focus, seed-stage activity, and rounds led. The conventional winner would have been General Catalyst, which topped the rankings in both capital deployed (~$839M) and rounds led (6). They earned their Honorable Mention, and we'll get to them.
But the data told a different story when we asked a different question: Who is helping to get important MedTech founders across the starting line?
The Case for Y Combinator
BillionToOne joined Y Combinator's Summer 2017 batch as an early-stage molecular diagnostics company. YC invested $120K for 7% equity — its standard seed-stage deal at the time.
Eight years later, BillionToOne IPO'd on November 6, 2025 at $60 per share (upsized, $5 above range), raising $314M and pricing at a ~$2.7B market cap. Within three weeks, shares peaked near $139, briefly pushing the market cap above $6B.
YC's $120K check valued BillionToOne at roughly $1.7M. The company's valuation grew approximately 1,600x from that seed round to its IPO — and briefly exceeded 3,500x at its November peak.
No traditional venture firm on our 2026 rankings generated anything close to that valuation growth. Not Andreessen Horowitz, which deployed ~$583M+ and exited Omada Health at ~$1.1B. Not General Catalyst, which led six rounds totaling ~$839M. Not even U.S. Venture Partners, which led the year in exit count with four IPOs totaling ~$4.1B.
Y Combinator saw BillionToOne when it was an idea and a small team. Everyone else saw it after it was already working.
Beyond BillionToOne
YC's medtech activity extends well beyond BillionToOne. In 2025, Y Combinator ran four batches (W25, X25, S25, F25), producing an estimated 20+ health and medtech startups — making YC the second most active seed-stage medtech investor in the country, behind only MedTech Innovator's 64-company cohort.
YC also appeared on the exit value tables with ~$2.7B in cumulative exit value — higher than Andreessen Horowitz (~$1.1B) despite deploying a fraction of the capital.
| Metric | Y Combinator | Context |
|---|---|---|
| BillionToOne exit value | ~$2.7B (IPO); ~$6B+ (peak) | From a $120K seed check |
| Seed-stage medtech deals (2025) | ~20+ | #2 behind MedTech Innovator |
| Cumulative exit value | ~$2.7B | Higher than a16z on the exit table |
| Capital deployed to achieve this | Minimal | Standard YC terms |
Why This Matters for Founders
The traditional MedTech fundraising narrative goes like this: find a specialized healthcare VC, find a warm intro, get on their calendar, pitch your regulatory pathway, and hope they understand your 510(k) timeline. YC inverts this model. The accelerator hosts an open call for applications; no warm introduction required. They select for the quality of the founding team and the size of the opportunity — not the fundraising stage or the founder's regulatory vocabulary.
If you're not connected to the elite VC networks, Y Combinator might be your in. The best first investor for your company might not be a healthcare specialist. It might be one that sees what your company could become before the sector-specific investors see what it currently is.
Honorable Mention: General Catalyst
By any conventional measure, General Catalyst was the dominant medtech investor of 2025. They earned the top position on two of our ranked tables:
- #1 in capital deployed: ~$839M across medtech rounds led or co-led
- #1 in rounds led: 6 rounds, twice as many as any other firm
General Catalyst's portfolio wasn't concentrated in a single thesis. They led investments across AI clinical decision-making (Aidoc, $150M), revenue cycle management (Commure, $200M), health benefits (Judi Health, $400M), at-home care (Sprinter Health, $55M), autonomous vision screening (Eyebot, $20M), and autoimmune care (WellTheory, $14M). Three different partners — Holly Maloney, Caitlin Donovan, and Candace Richardson — were named as lead investors, which signals institutional commitment rather than a single partner's side interest.
Rock Health named General Catalyst one of three "Goliath" investors of 2025 (alongside Andreessen Horowitz and Kleiner Perkins), noting that when GC participated, average deal sizes were significantly larger.
General Catalyst's Customer Value Fund (CVF) model also deserves attention. By deploying operational capital alongside financial capital, GC is building a differentiated relationship with portfolio companies that goes beyond board seats and quarterly check-ins.
Why Honorable Mention and not the winner? General Catalyst earns their spot for leading so many rounds; many VCs don't have the conviction or the bravery to lead so many investments. Without a leader for a round, nothing happens, so that's an important role. However, seed-stage startups face an even tougher challenge than those already grinding through the alphabet. It takes guts to lead a Series B medtech round, but taking a chance on a seed-stage MedTech startup is even more rare. Y Combinator takes those bets, and a surprising number of them pay off.
The Uncomfortable Implication
Our choice highlights a tension in how the industry thinks about "best investor."
If you measure by capital deployed, General Catalyst wins. If you measure by exit count, U.S. Venture Partners wins. If you measure by single-exit value, Sixth Street Partners wins ($5.9B from Caris Life Sciences alone). If you measure by medtech focus, a dozen specialist firms — Vensana Capital, ShangBay Capital, Catalyst Health Ventures — dominate with near-100% allocation.
But if you measure by impact to startups and patients — the metric that actually defines whether an investment was good — a seed accelerator that wrote a tiny check eight years ago — and still writes those checks — produced the most extraordinary outcomes of the year.
The two extremes of the investment spectrum — the smallest possible check (YC's seed) and the largest single bet (Sixth Street's growth round into Caris) — outperformed the portfolio-building middle on this metric. I hope other investors see this as a challenge.
Methodology
This award is based on data from our 2026 MedTech VC Rankings, which evaluated U.S. investors across seven dimensions using 2025 calendar-year data from public sources. Full methodology, sources, and ranked tables are available in that report.
This is the inaugural MedTech Connect Investor of the Year award. We welcome feedback.